Intensity Therapeutics Inc. (NASDAQ:INTS) Stock Rated “Moderate Buy” by Wall Street Analysts

Intensity Therapeutics Inc. (NASDAQ:INTS) has been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $7.00.

A number of research firms recently issued reports on INTS. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Monday, October 19th. Citigroup reiterated a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. Finally, HC Wainwright lifted their target price on Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th.

Intensity Therapeutics Trading Up 1.8%

Shares of INTS stock opened at $3.40 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00. The stock has a fifty day simple moving average of $3.77 and a two-hundred day simple moving average of $5.28. The firm has a market capitalization of $11.08 million, a PE ratio of -0.95 and a beta of 2.81. Intensity Therapeutics has a 52-week low of $3.00 and a 52-week high of $28.75.

Intensity Therapeutics (NASDAQ:INTS) last posted its earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.24). On average, analysts predict that Intensity Therapeutics will post -2.64 EPS for the current fiscal year.

About Intensity Therapeutics

Intensity Therapeutics, Inc (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer.

The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent.